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414 The Journal of Thoracic and Cardase series are the commonest form of evidence in cancer surgery, an area of
practice for which there are few randomized trials. There are pitfalls in the
presentation and interpretation of this clinical material, and in this article we
ighlight a number of them. We have used as a case study the body of literature
oncerning resection of mesothelioma. Mesothelioma is a disease that concerns us
reatly in Europe because we are facing an epidemic that will peak between 2010
nd 2015,1 and an even greater burden of disease will follow in parts of the
eveloping world. It is a grim cancer, and the quality of evidence is poor.2 However,
he need to understand the limitations of case series spreads much wider than
esothelioma.
Authors may recognize their work in the examples we present, and so we may
ell cause offence. This is not our intention. Readers may be tempted to search our
wn work for examples of errors, and they will find them—more egregious than any
f these. The alternative to citing real instances was for us to make them up or make
hem anonymous. However, then maybe some would say, “Surely no one would do
hat?” so they had to be real. We did not search systematically for examples; they
ome from articles we know through our research in mesothelioma. Finally, we have
ot shied away from using prominent examples, from leading authors, in leading
ournals. We needed to cite the best work or our concerns could be discounted as the
esult of a pedant’s trawl of the world’s literature. They are quoted with respect for
he authors and editors, who we know have broad shoulders.
resumption of Efficacy
adical surgery for mesothelioma was started in the 1970s.3 There have been no
andomized trials to show that radical surgery results in more survivors or longer
urvival than does no surgery.
The following statement (personal communication) from Eric Butchart, a pioneer
f the pleuropneumonectomy procedure (also called extrapleural pneumonectomy
r EPP), summarizes the situation: “We have recently analysed our experience with
oth pleuropneumonectomy and pleurectomy/decortication for mesothelioma. The
ery strong message from this analysis is that adjuvant therapy is essential in order
o achieve any degree of long term survival with either surgical procedure.”
The inference that no degree of long-term survival is achieved with surgery alone
s embedded in the statement by Butchart. If there is a perceived improvement in
urvival, logically it should be attributed to the adjuvant chemotherapy, and yet
uthors of surgical case series tend to conclude that surgery confers a survival
dvantage.
This belief would seem to be widespread. In the Methods section of the first
eport of a randomized trial of pemetrexed (in which a difference in survival was
ound between two regimens of chemotherapy), there is the statement that “candi-
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TSates for curative surgery” were excluded.4 The clear im-
lication is that curative surgery exists for these patients and
hat somewhere surgical cure is being achieved, but no
eference is cited.
When surgeons perform very radical surgery on many
atients, there is deep felt belief, held by medics and the
ublic alike, that the operation must be doing some good.
his is a very human tenet, which we call the presumption
f efficacy.
ead-time Shift
here is a variable interval between the onset of malignant
isease (which is hard to define) and the confirmation by
istologic diagnosis (typically the point in time from which
urvival is measured in nonoperated cases). When patients
ave a disease surrounded by therapeutic nihilism (as was
esothelioma) and a clinical team declares interest, refer-
als are made sooner and the diagnosis is likely to be made
arlier in the course of the disease. Historical series are drawn
rom the era before the active treatment was instigated, and
hese patients are likely to have received the diagnosis later
n the course of the disease. For example, respiratory phy-
icians in our own catchment area refer earlier now than
hey did in previous years because they know we are inter-
sted. It is known that we are interested in managing ma-
ignant effusion and in making the diagnosis of pleural
hickening as early as possible because we wrote about it in
he British Medical Journal.5 It is highly likely that the
nterval between tissue diagnosis and death is longer now
han it was previously for this reason alone. A case series
ollected in an earlier epoch would not be a reliable com-
arator against which to judge a present-day series.
The introduction to the most quoted surgical series af-
rms that the “natural history of malignant pleural mesothe-
ioma includes a median survival of 4–12 months without
ntervention.”6 There are three citations in support of this
tatement. They were published in 1980, 1984, and 1989, 10
o 20 years before the citation in 1999. Two of these
bservational series specifically comment on the delay and
ateness in making a diagnosis.
Statements such as “recent series show that overall sur-
ival is much longer than previously thought when [me-
othelioma] is diagnosed at an early stage”7 illustrate the
otential for confusion between lengthening survival by
herapy and by starting the clock sooner.
There are factors other than the vintage of the data. In
001 we identified all patients in two London thoracic
urgical centers in whom the diagnosis of mesothelioma
as made. The two sets of 127 and 234 patients were
imilar in age, sex, and the mix of tumor types.8 Neither
roup was treated aggressively; surgery at most was talc
leurodesis, and none had EPP. The survival of the two
roups was very different. There are various possible ex- a
The Journal of Thoraciclanations including chance, lead-time shift, and differing
istologic criteria, but these uncertainties only add to the
easons for exercising caution when using historical series
n comparisons. Either or both of these series of cases
iagnosed in the 5 years up to 2001 would be a more fair
omparison than the survival of patients diagnosed in the
970s and 1980s, but they might still be misleading. Com-
arisons against historical controls are inherently of limited
eliability.
omparison Groups May Have a Different Case Mix
here is another source of error in the use of historical series
n the EPP literature: We cannot be sure that the patients
ithin such series match those whom we now select for
adical surgery. In fact, we can be virtually certain that they
o not. It is very misleading if the case mix of the series put
p for comparison is not the same as the treated group. We
ould suggest that if any series is put up for comparison,
ue diligence must be exercised in ascertaining and report-
ng the extent to which it compares with the series being
ewly reported.
To make the point, let us look at one definable factor on
hich contemporary surgical series and historical survival
eries are different. The retrospective case series included
ll patients with a diagnosis of mesothelioma. More than
0% of patients would have had sarcomatoid histology, for
hich survival time is much reduced. We cannot know
xactly how many, so we cannot correct for it. Other than
etrieve all the pathologic material and have it re-examined
ith contemporary criteria, ideally “blind,” we can never
now. These sarcomatoid tumors are increasingly excluded
rom EPP in current practice.
To compare current surgical figures with an all-case histor-
cal series would be like reporting your present day results for
urgically treated non–small cell cancer and comparing 5-year
urvival with the natural history of all lung cancer, including
mall cell, from the 1970s before computed tomography and
efore positron emission tomography.
If the results of current practice are to be held up for
nspection against any comparator, historical or otherwise,
urely just as much care should be exercised in the analysis
f the comparison group as in that of the surgical series.
hese data may not be a finding of the research reported, but
hey are an intrinsic part of the evidence presented, and yet
ven the summary statistics may be quoted blandly without
dequate definition or caveat, as in the example cited: “The
atural history of malignant pleural mesothelioma includes
 median survival of 4 –12 months.”6 And yet it is done in
he case of mesothelioma without qualification or citation in
 recent “evidence based approach.”9
There is a consequence worse than inadvertently mis-
eading ourselves and our colleagues. Once such statements
ppear in reputable journals, it is reasonable for others to
and Cardiovascular Surgery ● Volume 133, Number 6 1415
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TSite them; they are regarded as fact. In 2006, by which time
he historical series quoted were 20 to 30 years out of date,
hey appeared on a public web page in similar terms
nd in the present tense: “survival averages four to 12
onths.”10
n Multimodality Cancer Treatment We Cannot Laud
Single Component
n the seven reported series of multimodality therapy we2
eviewed, radical surgery was combined with chemother-
py, radiotherapy, or both. Given this, it is not possible on
he basis of clinical observation to determine whether the
urgical component is conferring any advantage. For pa-
ients with mesothelioma, it would be as rational to attribute
ny perceived benefit to chemotherapy and radiotherapy,
nd to spare them the operation.
The series are reported as surgical series—the radical
urgery is center stage. However, any survival gain cannot
e attributed to radical surgery. If there is an advantage, it
hould be attributed to the full treatment package.
Intention-to-Treat” Analysis Is Required
t is common for authors of case series to report an analysis
f those patients who completed the full treatment schedule
nder review. They are reporting on the outcomes for a
articular management strategy. This is the contrary of
intention-to-treat” analysis, which is the generally ac-
epted standard of reporting for prospective studies and
andomized clinical trials. The lapse into “per-protocol”
nalysis is perhaps natural inasmuch as these are the data
etrieved by the surgical team—the patients who were
reated in a particular way.
The most obvious breach of intention-to-treat analysis is
o exclude from the survival curves the patients who died in
he immediate postoperative period.6
It goes further than that. An extreme scenario in me-
othelioma is as follows. Patients are selected for radical
urgery, and in some (but not all) EPP is performed. Of
hose who survive surgery, some (but not all) are selected to
ave radiotherapy. Some of these (but not all) continue to
urvive, and some (but not all) of these are well enough to be
iven chemotherapy and complete the course. Patients who
omplete treatment have a median survival much longer
han would have been expected in comparison with the
atural history of the disease. This survival is claimed as
vidence for the effectiveness of multimodality treatment.
The patient pool under consideration is reduced at each
f multiple stages through both clinical selection and sur-
ival. The patients had to be worked up, undergo, survive,
nd recover from each of the first two components and then
e worked up for and undergo the final component. All take
ime (maybe as much as 3 months each), each step may
liminate some patients, and each intervention takes a toll a
416 The Journal of Thoracic and Cardiovascular Surgery ● Junn patients. Those who arrive at the end are clinically and
elf-selectedly survivors.
There may be a place for per-protocol analysis in eval-
ation of the mechanics of some surgical techniques, but it
an surely have no place in the evaluation of multimodality
herapy as arduous and drawn out as that offered for me-
othelioma. Intention-to-treat analysis is essential.
ace Validity
sually we like to understand how an operation works.
fter hip replacement, the lame walk; after cataract extrac-
ion, the blind see; and relief of aortic stenosis results in
ymptom relief and much longer survival. These all make
omplete sense to surgeons, who are practical people; we
refer there to be face validity to what we do.
A fundamental principle of curing cancer by surgery has
een eradication of all disease at operation. There may be an
merging role of reducing tumor bulk as an adjunct to other
reatment, but for curative surgery the first principle is to clear
ll the cancer. It is for that reason that certain forms of cancers
or which radical surgery used to be performed with intent to
ure are no longer operated on. These include small-cell lung
ancer, lymphoma, and many cases of breast cancer.
These cancers are characterized as already being sys-
emic diseases at presentation, and the cancer is thus beyond
he surgeon’s knife. That distinction, between the surgically
urable and incurable cancers, has been negotiated since the
arly reports of radical surgery for mesothelioma. On the face of
t, the creeping nature of mesothelioma and the arbitrariness
f the anatomic clearance of the endothoracic fascia make it
n unlikely candidate for surgical cure. The onus to counter
hat argument is on those who believe that EPP can cure.
Analysis of an operated series revealed three factors
ssociated with longer postoperative survival: histologic
ype, mediastinal lymph node involvement, and surgical
learance, in that order of effect size.6 The smallest survival
ifference was associated with whether the resection mar-
ins were clear (R0) or not (R1).
That the difference between survival time for R1 and R0
ie, the difference between the operation failing to eradicate
ll disease and the operation possibly eradicating all dis-
ase) is smaller than the differences attributed to nodal
tatus and histology undermines the notion that this cancer
ends itself to surgical cure.
actors for “Case Selection” Should Be Tested
n a New Data Set
espected surgeons believe that there is evidence on which
o select patients for EPP and cite the 1999 report by David
ugarbaker and associates.6 It behooves us, therefore, to
ook carefully at the evidence on which they rely. The report
oncerns 176 patients who were the survivors from 183
ases selected for surgery from an unspecified but presum-
bly large denominator, given the reputation of this group.
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TSThree factors were found in multivariable analysis to be
ssociated with survival. These were used to classify patients
nto groups with 0, 1, 2, or 3 of these characteristics: epithelioid
istology, no extrapleural nodes, and clear resection margins.
here were significant differences among the four groups thus
reated. However, inasmuch as the factors were derived from
multivariable analysis and then used to categorize the same
ata, this is completely unsurprising. As a numerical argument
t is circular. To prove the validity of these factors as predic-
ors, they should be applied to a new series, not to the one from
hich they were derived. To be fair, this point is made by the
uthors6 but does not seem to have been heeded.
Importantly, even if validated as factors associated with
urvival after EPP, such analysis cannot be used to select
hose likely to “benefit most” from EPP because the notion
f differential benefit is based entirely on the presumption of
fficacy.
riteria for Case Selection Must Be Applicable Before
urgery
here is a separate flaw in the promulgation of these factors as
means of selecting patients as those believed to benefit most
rom radical surgery: they were all defined or refined postop-
ratively. Resection margins can only be defined post hoc,
ymph node status is revised as part of pTNM staging, and with
ll of the resected tumor in hand, more patients will be reclas-
ified as having sarcomatoid or mixed histology.
If we are to have a set of criteria on which to select or
ounsel patients, they must be available before surgery and
e amenable to validation, indeed have been validated,
efore they can be used.
ssociation Is Not Causation
emorial Sloan-Kettering has analyzed 945 patients with
esothelioma over the past 15 years. Surgical resection was
ssociated with improved survival.11 Does this prove that
urgery favorably influenced the outcome for these patients?
he choice of words, “Multimodality therapy including
urgery yielded a median survival of . . .” [our emphasis]
uggests that the writer believed so.
The problem is that many factors are used by experi-
nced and knowledgeable teams when they decide to oper-
te on one patient but not another. These factors include all
vailable clinical information but cannot all be accounted
or: some are not consciously recognized, some are not
ade explicit, and some are unknown unknowns.
In Flores’ Cox model,11 perhaps it was not the operation
hat was the determinant but that a sage surgeon, supported
y many investigations and many colleagues, deemed the
atient a candidate for surgery. It would be indeed surpris-
ng if these choices did not produce a cohort of patients who
id better than those not selected, that is, unless the authors
re suggesting that the decision to operate is some sort of
aphazard event. Hence association is the correct word.
The Journal of Thoracicope Springs Eternal in the Human Breast
inally, it is argued that surgeons must offer hope—but surely
ot false hope by obscuring the truth from those who are
ntitled to know it. Active treatment for which there is no
vidence of clinical benefit is sometimes preferred to inaction
or “psychological reasons.” EPP is too severe to be justified on
hese grounds, whether it is to comfort the patient or the surgeon!
onclusions
oo often, retrospective reports of surgical series lack objec-
ivity and start from a presumption of efficacy. At worst, they
re a form of self-justification, not evidence. There is an inher-
nt underlying assumption that the operation must be doing
omething to help rather than harm, or how could we face
urselves, let alone our patients? Patients, too, find it hard to
ccept that the operation they have been through may be
navailing or that they face a condition for which there is no
ecognized means of cure.
One solution to all of the problems raised might be a
andomized trial. A randomized clinical trial provides a
ontemporary matched comparison group with a similar
ase mix, avoids the pitfalls of retrospective multivariable
nalysis, and is analyzed on an intention-to-treat basis.
here are many forms of evidence for what we as surgeons
o,12,13 but once removed from rather obvious cause-and-
ffect, when benefits are small and treatments are complex,
t is unlikely that a case series will give secure evidence.
We have to conclude that there is as yet no reliable
vidence for the effectiveness of radical surgery for me-
othelioma, and patients should be informed of that fact.
ur belief is that in the context of mesothelioma, radical
urgery should be offered only in a trial in which its effec-
iveness can be tested. Some worry that randomized trials
ave the effect of disadvantaging half the patients. Where
hey are wrong is in thinking that they know which half.
A total of 126 trials of cancer treatments have been
eported to date in 36,567 children.14 Who did better, those
n the new treatments or those in the control groups? The
nswer is that the trial results are evenly spread either side
f zero. For each group of patients denied benefit, another
as spared a less effective novel treatment.
We owe it to today’s patients with mesothelioma to get
t right. The epidemic is still rising in Europe and there will
e many patients in the next 10 to 20 years. We owe it to the
est of the world where asbestos was less well controlled or
emains uncontrolled. Equally important is this: we owe it to
ur own scientific integrity.
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